The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting

FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting

December 1, 2021 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence 2021.

You Might Also Like
  • FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
  • FDA Update: New Drug Approvals, New & Expanded Indications, & More
  • FDA Update: FDA Delays Baricitinib Review & Removes Bupropion & Varenicline Warnings
Also By This Author
  • Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD

In a session updating the audience on a variety of areas overseen by the FDA, many attendee questions had to do with the decision earlier this year to issue a Boxed Warning for the whole class of JAK inhibitors approved for rheumatic conditions: tofacitinib, baricitinib and upadacitinib. The warning is related to major heart events, malignancy, blood clots and mortality. The data, the officials said, also warranted limiting the indications: These drugs must only be used for patients with an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitors.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The warnings, the most prominent issued by the FDA, came after a post-marketing research safety study on tofacitinib revealed safety concerns.1 Tofacitinib was found to bring a 33% higher risk of major adverse cardiovascular events and a 48% increased risk of malignancy (except for non-melanoma skin cancers) compared with TNF inhibitors, the research found.

A major question: What was the rationale for extending the warning to the other two drugs, too?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Yes, they are all JAK inhibitors, but they are different JAKs, and really, is it fair to cover them all with a significant class-effect warning?” one attendee asked.

Dr. Rajpal

“Given the seriousness of these safety concerns,” said Anil Rajpal, MD, MPH, medical team leader in the rheumatology and transplant medicine division at the FDA, “and the cumulative knowledge about the dose- and exposure-dependent toxicities, we considered that these findings are relevant to baricitinib and upadacitinib—in other words, to be class effects for the products for the treatment of inflammatory conditions.”

Dr. Nikolov

Nikolay Nikolov, MD, director of the rheumatology and transplant medicine division at the FDA, said the rigorous nature of the data dictated the broader warning. “We certainly recognize the importance of tofacitinib and all the JAK inhibitors in the management of inflammatory conditions,” he said. “However, we also recognize that we now have the safety data, which are derived from a prospective, randomized controlled study that was specifically designed and conducted to compare the safety of tofacitinib to that of TNF inhibitors. And the data are compelling and robust to support the meaningful comparisons of adverse events of special interest.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Drug Updates, Meeting Reports, Rheumatoid Arthritis, Safety Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RA, avacopan, baricitinib, boxed warnings, JAK inhibitors, Tofacitinib, upadacitinib

You Might Also Like:
  • FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
  • FDA Update: New Drug Approvals, New & Expanded Indications, & More
  • FDA Update: FDA Delays Baricitinib Review & Removes Bupropion & Varenicline Warnings
  • U.S. FDA Declines to Approve Eli Lilly & Incyte Arthritis Drug

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)